Orforglipron — sold as Foundayo — is the rare weight-loss medication whose instructions are genuinely simple: one tablet, once a day, whenever you like. But the dosing schedule behind that simplicity is deliberate and worth understanding, because the slow climb from starting dose to maintenance dose is what makes the medication tolerable. Here is the label’s dosing plan translated into plain English.
The Basics
- Once daily, any time of day.
- With or without food — no fasting, no water rules, no 30-minute waits.
- Swallow the tablet whole. Do not break, crush, or chew it.
- Don’t combine with any other GLP-1 medication.
The freedom from food and water rules comes from orforglipron’s chemistry — it is a small molecule rather than a peptide, so stomach acid doesn’t destroy it the way it would oral semaglutide. If you’re curious why that distinction matters more broadly, our oral vs injectable guide covers it.
The Dose Escalation Schedule
The label prescribes a stepwise climb, holding each dose for at least 30 days before moving up:
| Step | Dose | Minimum Duration |
|---|---|---|
| Start | 0.8 mg once daily | At least 30 days |
| Step 2 | 2.5 mg once daily | At least 30 days |
| Step 3 | 5.5 mg once daily | At least 30 days |
| Step 4+ | 9 mg, 14.5 mg, or 17.2 mg once daily | At least 30 days per step, as advised |
The maximum dose is 17.2 mg once daily. Not everyone climbs to the top — your prescriber sets the target based on how you respond and what you tolerate, and some women do well holding at a middle dose. The whole point of the 30-day holds is to let your GI system adapt; rushing the schedule is how nausea wins.
A Note on Trial Doses vs. Tablet Doses
If you read about the ATTAIN trials, you saw doses like 36 mg — and the approved tablets top out at 17.2 mg. That is not a downgrade: the investigational capsules and the commercial tablets deliver equivalent exposure at different labeled strengths (the 36 mg trial capsule corresponds to the 17.2 mg approved tablet). Worth knowing so the numbers don’t alarm you — and another reason gray-market products quoting trial doses are a red flag.
Missed Doses
Missing a single day is not a crisis — resume your normal schedule. The label’s important rule kicks in at a week: if you miss seven or more consecutive doses, restart the escalation at a lower dose rather than resuming your previous level, to avoid the GI side effects returning at full strength. Coordinate the specifics with your prescriber.
The Birth Control Rule Most Coverage Skips
Orforglipron delays stomach emptying, which can affect absorption of birth control pills. The label advises switching to a non-oral contraceptive or adding a barrier method for 30 days after starting and for 30 days after each dose increase. Look at the escalation table above and do the math: a woman titrating through four steps could spend several separate months in barrier-method windows. Plan for it rather than discovering it. More context in peptides and birth control.
Medication Interactions Worth Flagging to Your Prescriber
The label includes dose-adjustment guidance around CYP3A4 — a liver enzyme system that many common drugs influence. Strong CYP3A4 inhibitors (certain antifungals and antibiotics among them) cap the maximum orforglipron dose, while CYP3A4 inducers can reduce its effectiveness. This is exactly the kind of detail a prescriber and pharmacist catch in seconds — bring your full medication list, including supplements.
What to Expect While Titrating
GI side effects — nausea, constipation, diarrhea — cluster around dose increases and typically ease as your body adjusts. Practical mitigations women report and clinicians commonly suggest: smaller meals, less fatty food around dose-up weeks, steady hydration, and not scheduling a dose increase the week of a big event. If side effects stay disruptive, holding longer at the current dose is a legitimate strategy to raise with your prescriber — the 30-day figure is a minimum, not a deadline. For the fuller picture of expectations, see the Foundayo FAQ and our complete guide for women.